Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIS-RA: Nipocalimab in Active Rheumatoid Arthritis
NCT04991753Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of nipocalimab in rheumatoid arthritis (RA), sponsored by Janssen Pharmaceutical. Started Oct 2021; status: completed.
02
Drugs
nipocalimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04991753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991753.